

Kyowa Kirin Co., Ltd.

Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025

(January 1, 2025 - December 31, 2025)

- These materials were made as a supplement to the Kessan Tanshin (Consolidated Financial Summary, IFRS), disclosed at the Tokyo Stock Exchange on February 9, 2026 for Fiscal 2025, from January 1, 2025 to December 31, 2025.
- This document is an English translation of the Japanese-language original.
- The statements, including earnings forecasts, contained in these materials are based on the information currently available to the Company and on certain assumptions deemed to be reasonable by management. As such, they do not constitute guarantees by the Company of future performance. Actual results may differ materially from these projections for a wide variety of reasons.
- Figures presented in these materials have been rounded to the nearest tenth
- Figures inside parenthesis presented in these materials indicate negative values.
- Change amount in these materials presents change amount compared to the same period of the previous fiscal year.

Index	Page
I. Consolidated Financial Results	
1. Trends in consolidated profit	1
2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)	2
3. Revenue by regional control function	3
4. Capital expenditures and intangible assets investment, depreciation and amortization	3
5. Number of employees by regional control function	3
II. Consolidated Statement of Cash Flows	3
III. Status of Main Products	
1. Revenue by Products	4
2. Revenue by Location	5
3. Collaboration Products	6
IV. R&D Pipeline	7

The average exchange rates for each period were as follows:

Unit: Yen

	FY 2024 results				FY 2025 results				FY2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
USD	147	151	151	151	154	150	149	150	150
GBP	187	191	193	193	193	193	195	197	205
EUR	160	163	164	164	161	162	165	168	180

Contact
 Kyowa Kirin Co., Ltd.
 Corporate Communications Department
 Tel +81 3 5205 7206

I. Consolidated Financial Results

1. Trends in consolidated profit

<Accumulative>

The “★” symbol indicates financial KPIs (numerical guidance) that were set as targets in the FY2021-2025 Medium Term Business Plan.

Unit: Billions of yen

	FY 2024 results				FY 2025 results							
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan-Dec	Change amount	Rate of change	Jan - Dec latest forecasts	% of forecasts
Revenue	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	0%	478.0	104%
★ CAGR (compared to FY 2020)	-	-	-	11.7%	-	-	-	9.3%	-	-	8.5%	-
Cost of sales	(25.6)	(59.5)	(94.0)	(132.6)	(24.6)	(61.9)	(90.1)	(127.9)	4.7	(4)%	(126.0)	102%
Gross profit	80.0	173.5	268.8	362.9	80.1	168.8	259.4	368.9	5.9	2%	352.0	105%
Gross profit to revenue ratio	75.8%	74.5%	74.1%	73.2%	76.5%	73.2%	74.2%	74.2%	-	-	73.6%	-
Selling, general and administrative expenses	(40.2)	(83.2)	(123.6)	(167.5)	(42.0)	(82.8)	(121.5)	(165.4)	2.1	(1)%	(166.0)	100%
Research and development expenses	(23.3)	(49.2)	(74.3)	(103.5)	(28.6)	(52.5)	(76.8)	(101.2)	2.4	(2)%	(107.0)	95%
★ R&D expense ratio	22.1%	21.1%	20.5%	20.9%	27.3%	22.8%	22.0%	20.4%	-	-	22.4%	-
Share of profit (loss) of investments accounted for using equity method	0.9	3.1	3.5	3.5	(0.9)	1.5	1.0	0.8	(2.8)	(78)%	1.0	79%
Core Operating Profit ^{*1}	17.4	44.1	74.4	95.4	8.6	35.0	62.0	103.1	7.7	8%	80.0	129%
★ Core operating profit ratio	16.5%	18.9%	20.5%	19.3%	8.2%	15.2%	17.7%	20.7%	-	-	16.7%	-
Other income	2.6	4.4	13.3	13.1	0.4	0.6	0.7	1.1	(12.0)	(92)%		
Other expenses	(2.8)	(4.7)	(16.9)	(19.3)	(1.6)	(12.9)	(14.7)	(18.0)	1.3	(7)%		
Finance income (costs)	0.8	2.6	0.8	(5.8)	0.4	(0.7)	(0.1)	1.1	6.8	-		
Profit before tax	18.1	46.5	71.6	83.5	7.9	22.0	47.9	87.2	3.8	5%	74.0	118%
Income tax expense	(3.5)	(8.7)	(15.7)	(23.6)	(1.7)	(5.7)	(15.3)	(20.2)	3.4	(14)%	(17.0)	119%
Ratio of income tax burden	19.2%	18.8%	21.9%	28.3%	21.5%	25.7%	32.0%	23.1%	-	-	23.0%	-
Profit	14.6	37.8	55.9	59.9	6.2	16.3	32.6	67.0	7.2	12%	57.0	118%
Profit to revenue ratio	13.9%	16.2%	15.4%	12.1%	5.9%	7.1%	9.3%	13.5%	-	-	11.9%	-

EPS (¥/share) 27.26 70.76 105.20 113.06 11.78 31.18 62.28 128.07 15.01 - 108.91

Core EPS (¥/share)^{*2} 27.46 71.16 110.52 121.44 13.57 48.63 80.46 152.90 31.46 - 119.23

Annual dividend (¥/share) 58.00 62.00 4.00 60.00

★ Dividend payout ratio (%)^{*3} 47.8 40.5 (7.2) 50.3

★ ROE (%) 7.1 7.7 0.6 6.6

Target of 40%
10% or higher

*1 Core operating profit = Gross profit - Selling, general and administrative expenses - Research and development expenses + Share of profit (loss) of investments accounted for using equity method.

*2 Core EPS is calculated as an indicator showing recurring profitability by dividing core profit (determined by subtracting “other income,” “other expenses” and the related “income tax expense” from “profit”) by the average number of shares during the period.

*3 Dividend payout ratio is shown based on core EPS.

<Quarterly>

Unit: Billions of yen

	FY 2024 results				FY 2025 results				Change amount	Rate of change
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec		
Revenue	105.6	127.4	129.8	132.8	104.7	125.9	118.8	147.4	14.6	11%
Cost of sales	(25.6)	(33.9)	(34.5)	(38.6)	(24.6)	(37.3)	(28.2)	(37.9)	0.7	(2)%
Gross profit	80.0	93.5	95.3	94.2	80.1	88.7	90.6	109.5	15.3	16%
Gross profit to revenue ratio	75.8%	73.4%	73.4%	70.9%	76.5%	70.4%	76.3%	74.3%	-	-
Selling, general and administrative expenses	(40.2)	(43.1)	(40.4)	(43.9)	(42.0)	(40.8)	(38.7)	(43.9)	0.0	(0)%
Research and development expenses	(23.3)	(25.9)	(25.0)	(29.3)	(28.6)	(23.9)	(24.3)	(24.3)	4.9	(17)%
★ R&D expense ratio	22.1%	20.4%	19.3%	22.0%	27.3%	19.0%	20.5%	16.5%	-	-
Share of profit (loss) of investments accounted for using equity method	0.9	2.2	0.4	0.0	(0.9)	2.5	(0.6)	(0.2)	(0.2)	-
Core operating profit	17.4	26.7	30.3	21.0	8.6	26.4	27.0	41.1	20.1	96%
★ Core operating profit ratio	16.5%	21.0%	23.3%	15.8%	8.2%	21.0%	22.7%	27.9%	-	-
Other income	2.6	1.8	8.9	(0.2)	0.4	0.2	0.2	0.3	0.5	-
Other expenses	(2.8)	(1.9)	(12.2)	(2.4)	(1.6)	(11.3)	(1.9)	(3.3)	(0.8)	35%
Finance income (costs)	0.8	1.8	(1.9)	(6.5)	0.4	(1.2)	0.7	1.1	7.7	-
Profit before tax	18.1	28.4	25.1	11.9	7.9	14.1	25.9	39.3	27.4	231%
Income tax expense	(3.5)	(5.3)	(6.9)	(7.9)	(1.7)	(4.0)	(9.7)	(4.9)	3.1	(39)%
Profit	14.6	23.1	18.1	4.0	6.2	10.2	16.3	34.4	30.5	768%
Profit to revenue ratio	13.9%	18.2%	14.0%	3.0%	5.9%	8.1%	13.7%	23.4%	-	-

I. Consolidated Financial Results

2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)

<Accumulative - New Core Base>

<Accumulative - New Core Base>											Unit: Billions of yen		FY 2028 forecasts	
	FY 2024 results				FY 2025 results						FY 2026 forecasts			
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Rate of change	Jan - Dec	Rate of change		
Revenue	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	0%	520.0	5%	Early 20% range	
Cost of sales	(25.6)	(59.5)	(94.0)	(132.6)	(24.6)	(61.9)	(90.1)	(127.9)	4.7	(4)%	(129.0)	1%		
Gross profit	80.0	173.5	268.8	362.9	80.1	168.8	259.4	368.9	5.9	2%	391.0	6%		
Gross profit to revenue ratio	75.8%	74.5%	74.1%	73.2%	76.5%	73.2%	74.2%	74.2%	-	-	75.2%	-		
Selling, general and administrative expenses ²	(38.8)	(79.7)	(117.7)	(160.0)	(40.4)	(79.5)	(116.5)	(157.9)	2.1	(1)%	(169.0)	7%		
Research and development expenses	(23.3)	(49.2)	(74.3)	(103.5)	(28.6)	(52.5)	(76.8)	(101.2)	2.4	(2)%	(122.0)	21%		
★ R&D expense ratio	22.1%	21.1%	20.5%	20.9%	27.3%	22.8%	22.0%	20.4%	-	-	23.5%	-		
Core operating profit	17.9	44.5	76.8	99.4	11.2	36.8	66.1	109.8	10.4	10%	100.0	(9)%		
★ Core operating profit ratio	16.9%	19.1%	21.2%	20.1%	10.7%	16.0%	18.9%	22.1%	-	-	19.2%	-		
Amortization (intangible assets) ³	(1.4)	(3.5)	(6.0)	(7.6)	(1.7)	(3.4)	(5.1)	(7.6)	0.0	(0)%	(11.0)	45%		
Share of profit (loss) of investments accounted for using equity method	0.9	3.1	3.5	3.5	(0.9)	1.5	1.0	0.8	(2.8)	(78)%	(2.0)	-		
Other income	2.6	4.4	13.3	13.1	0.4	0.6	0.7	1.1	(12.0)	(92)%				
Other expenses	(2.8)	(4.7)	(16.9)	(19.3)	(1.6)	(12.9)	(14.7)	(18.0)	1.3	(7)%				
Finance income (costs)	0.8	2.6	0.8	(5.8)	0.4	(0.7)	(0.1)	1.1	6.8	-				
Profit before tax	18.1	46.5	71.6	83.5	7.9	22.0	47.9	87.2	3.8	5%	95.0	9%		
Income tax expense	(3.5)	(8.7)	(15.7)	(23.6)	(1.7)	(5.7)	(15.3)	(20.2)	3.4	(14)%	(20.0)	(1)%		
Ratio of income tax burden	19.2%	18.8%	21.9%	28.3%	21.5%	25.7%	32.0%	23.1%	-	-	-	-		
Profit	14.6	37.8	55.9	59.9	6.2	16.3	32.6	67.0	7.2	12%	75.0	12%		
Profit to revenue ratio	13.9%	16.2%	15.4%	12.1%	5.9%	7.1%	9.3%	13.5%	-	-	14.4%	-		
ROE(%)	7.1				7.7				0.6		8.2		7% or higher Progressive payout of 4% or more	
★ROE(%) ※ Three-year average	8.2				8.3				0.1		7.7			
★DOE(%) ⁴	3.6				3.8				0.2		4.1			

<Accumulative - New Core Base>

	FY 2024 results				FY 2025 results						FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Rate of change	Jan - Dec	Rate of change
Core operating profit	17.9	44.5	76.8	99.4	11.2	36.8	66.1	109.8	10.4	10%	100.0	(9)%
Income tax expense	(3.4)	(8.4)	(16.8)	(28.1)	(2.4)	(9.5)	(21.1)	(25.4)	2.7	(10)%	(20.0)	(21)%
Ratio of income tax burden	19.2%	18.8%	21.9%	28.3%	21.5%	25.7%	32.0%	23.1%	-	-	-	-
Core Profit ¹	14.5	36.2	60.0	71.3	8.8	27.4	44.9	84.4	13.1	18%	80.0	(5)%
Core EPS (¥/share) ⁵	26.93	67.74	112.93	134.72	16.83	52.25	85.85	161.28	26.56	-	152.82	-

*1 We have adopted core indicators as performance metrics that offer better comparability with global pharma, reflecting group's sustainable profitability.

The new core operating profit is calculated by deducting selling, general and administrative expenses (excl. amortization of intangible assets) and research and development expenses from gross profit, and further excluding non-recurring items determined by the company.

The new core profit for the period is calculated by deducting income tax expense attributable to the relevant core operating profit from the new core operating profit.

*2 Selling, general and administrative expenses do not include amortization of intangible assets.

*3 Amortization of marketing rights is presented as amortization of intangible assets.

*4 DOE is calculated by dividing the dividend amount by the beginning-of-period capital.

*5 The new core EPS is calculated by dividing the new core profit for the period by the weighted average number of shares outstanding during the period.

*6 For the actual results in 2024 and 2025 and the forecast for 2026, the Company did not exclude any items as non-recurring gains or losses, as determined by the Company.

<Quarterly - New Core Base>

	FY 2024 results				FY 2025 results						FY 2026 forecasts	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount	Rate of change	Jan - Dec	Rate of change
Revenue	105.6	127.4	129.8	132.8	104.7	125.9	118.8	147.4	14.6	11%	-	-
Cost of sales	(25.6)	(33.9)	(34.5)	(38.6)	(24.6)	(37.3)	(28.2)	(37.9)	0.7	(2)%	-	-
Gross profit	80.0	93.5	95.3	94.2	80.1	88.7	90.6	109.5	15.3	16%	-	-
Gross profit to revenue ratio	75.8%	73.4%	73.4%	70.9%	76.5%	70.4%	76.3%	74.3%	-	-	-	-
Selling, general and administrative expenses	(38.8)	(40.9)	(37.9)	(42.3)	(40.4)	(39.1)	(37.0)	(41.4)	0.9	(2)%	-	-
Research and development expenses	(23.3)	(25.9)	(25.0)	(29.3)	(28.6)	(23.9)	(24.3)	(24.3)	4.9	(17)%	-	-
★ R&D expense ratio	22.1%	20.4%	19.3%	22.0%	27.3%	19.0%	20.5%	16.5%	-	-	-	-
Core operating profit	17.9	26.7	32.3	22.6	11.2	25.6	29.2	43.8	21.2	94%	-	-
★ Core operating profit ratio	16.9%	20.9%	24.9%	17.0%	10.7%	20.3%	24.6%	29.7%	-	-	-	-
Amortization (intangible assets)	(1.4)	(2.1)	(2.4)	(1.6)	(1.7)	(1.7)	(1.7)	(2.5)	(0.9)	54%	-	-
Share of profit (loss) of investments accounted for using equity method	0.9	2.2	0.4	0.0	(0.9)	2.5	(0.6)	(0.2)	(0.2)	-	-	-
Other income	2.6	1.8	8.9	(0.2)	0.4	0.2	0.2	0.3	0.5	-	-	-
Other expenses	(2.8)	(1.9)	(12.2)	(2.4)	(1.6)	(11.3)	(1.9)	(3.3)	(0.8)	35%	-	-
Finance income (costs)	0.8	1.8	(1.9)	(6.5)	0.4	(1.2)	0.7	1.1	7.7	-	-	-
Profit before tax	18.1	28.4	25.1	11.9	7.9	14.1	25.9	39.3	27.4	231%	-	-
Income tax expense	(3.5)	(5.3)	(6.9)	(7.9)	(1.7)	(4.0)	(9.7)	(4.9)	3.1	-	-	-
Profit	14.6	23.1	18.1	4.0	6.2	10.2	16.3	34.4	30.5	768%	-	-
Profit to revenue ratio	13.9%	18.2%	14.0%	3.0%	5.9%	8.1%	13.7%	23.4%	-	-	-	-

<Quarterly - New Core Base>

	FY 2024 results				FY 2025 results						FY 2026 forecasts	
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount	Rate of change	Jan - Dec	Rate of change
Core operating profit	17.9	26.7	32.3	22.6	11.2	25.6	29.2	43.8	21.2	94%	-	-
Income tax expense	(3.5)	(4.9)	(6.9)	(7.9)	(1.7)	(4.0)	(9.7)	(4.9)	3.1	-	-	-
Core profit	14.5	21.7	23.8	11.3	8.8	18.5	17.6	39.5	28.2	248%	-	-

3. Revenue by regional control function

<Accumulative>

Unit: Billions of yen

	FY 2024 results				FY 2025 results					FY 2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec
Japan	31.6	65.3	98.0	134.7	27.2	58.4	89.7	122.5	(12.1)	111.5
North America	32.3	79.9	120.1	174.4	35.5	88.4	129.9	192.5	18.1	211.0
EMEA	16.7	36.9	65.7	84.9	19.7	37.0	62.4	83.7	(1.3)	78.5
Others	25.0	50.9	78.9	101.5	22.3	46.9	67.5	98.1	(3.4)	119.0
Total consolidated revenue	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	520.0
Japan (location of customer)	34.3	68.6	100.9	141.2	28.3	63.1	96.0	128.8	(12.4)	120.0
Overseas (location of customer)	71.3	164.4	261.9	354.4	76.4	167.6	253.4	368.0	13.6	400.0
Overseas ratio	68%	71%	72%	72%	73%	73%	73%	74%	-	77%

* Revenue by regional control function is classified based on consolidated revenue from products of regional control functions in the One Kyowa Kirin (OKK) matrix global management structure, which combines a regional organization, a functional organization, and a product organization (product franchises).

* EMEA consists of Europe, the Middle East, Africa, etc.

* Others consists of revenue from technology out-licensing, revenue from APAC, hematopoietic stem cell gene therapy (revenue from Orchard Therapeutics), original equipment manufacturing, etc.

* Revenue that was classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

<Quarterly>

Unit: Billions of yen

	FY 2024 results				FY 2025 results				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount
Japan	31.6	33.7	32.8	36.6	27.2	31.2	31.3	32.8	(3.8)
North America	32.3	47.6	40.2	54.3	35.5	52.8	41.5	62.6	8.3
EMEA	16.7	20.1	28.8	19.2	19.7	17.3	25.3	21.3	2.1
Others	25.0	26.0	28.0	22.6	22.3	24.5	20.6	30.6	8.0
Total consolidated revenue	105.6	127.4	129.8	132.8	104.7	125.9	118.8	147.4	14.6

4. Capital expenditures and intangible assets investment, depreciation and amortization

Unit: Billions of yen

	FY 2024 results				FY 2025 results				FY 2026 forecasts
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Dec
Capital expenditures (property, plant and equipment) ¹	4.9	12.3	19.0	29.5	8.2	14.9	22.9	35.0	33.9
Intangible assets investment	17.7	21.9	25.5	79.3	1.3	9.9	21.3	48.1	18.3
Total	22.5	34.2	44.6	108.7	9.4	24.9	44.2	83.1	52.2
Depreciation (property, plant and equipment)	3.7	7.4	11.0	14.8	3.8	7.6	11.7	15.8	16.8
Amortization (intangible assets)	2.0	4.7	7.8	10.0	2.3	4.7	7.1	10.4	15.0
Of which, sales right ²	1.4	3.5	6.0	7.6	1.7	3.4	5.1	7.6	11.1
Total	5.6	12.1	18.8	24.8	6.1	12.3	18.8	26.1	31.7

¹ Acquisitions of right-of-use assets are not included.

² From 2026 onward, amortization of intangible assets will be presented as a separate line item in the consolidated statement of profit or loss.

5. Number of employees by regional control function

	FY 2024 results				FY 2025 results				
	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	As of Mar 31	As of Jun 30	As of Sep 30	As of Dec 31	Change amount
Japan	4,090	4,103	4,093	4,020	3,898	3,890	3,882	3,508	(512)
North America	648	664	664	668	709	678	699	706	38
EMEA	543	548	553	547	538	540	544	551	4
Others	873	866	877	434	375	381	387	397	(37)
Total	6,154	6,181	6,186	5,669	5,520	5,489	5,512	5,161	(508)

* Others consists of number of employees of APAC subsidiaries, Orchard Therapeutics, etc.

* Number of employees that were classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

II. Consolidated Statement of Cash Flows

Unit: Billions of yen

Unit: Billions of yen									
	FY 2024 results				FY 2025 results				
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount
Cash flows from operating activities	19.2	46.9	69.6	67.9	7.4	39.8	69.6	100.0	32.1
Cash flows from investing activities	(50.3)	(80.5)	(95.8)	(142.4)	(21.5)	(34.7)	(41.6)	(92.6)	49.8
Cash flows from financing activities	(41.3)	(63.2)	(83.7)	(84.7)	(16.5)	(17.2)	(33.6)	(36.9)	47.8
Effect of exchange rate changes on cash and cash equivalents	2.5	4.9	3.1	0.8	0.3	2.0	1.2	3.5	2.7
Net increase (decrease) in cash and cash equivalents	(70.0)	(91.9)	(106.8)	(158.4)	(30.3)	(10.1)	(4.5)	(25.9)	132.5
Cash and cash equivalents at beginning of period	403.1	403.1	403.1	403.1	244.7	244.7	244.7	244.7	(158.4)
Cash and cash equivalents at end of period	333.1	311.1	296.3	244.7	214.4	234.6	240.2	218.8	(25.9)

III. Status of Main Products

1. Revenue by Products

<Accumulative>

Unit: Billions of yen

	FY 2024 results				FY 2025 results							FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Products ^{*1}	93.4	208.7	327.9	446.8	91.8	205.2	310.1	438.4	(8.4)	425.7	103%	445.1	2%
Crysvita	37.8	90.9	134.9	196.6	42.4	99.8	146.7	216.4	19.8	210.2	103%	235.4	9%
Poteligeo	8.6	19.1	29.1	39.9	9.8	21.6	33.7	45.7	5.8	45.4	101%	54.6	20%
Libmeldy/Lenmeldy	1.1	1.4	2.2	3.3	2.1	4.4	4.4	6.4	3.2	6.9	94%	10.0	56%
Nourianz	1.6	3.5	6.2	8.8	2.0	4.6	6.9	9.5	0.7	8.2	116%	7.4	(22)%
PHOZEVEL	0.6	1.7	2.9	4.7	1.5	3.7	5.9	8.2	3.6	8.9	92%	11.6	41%
Duvroq	2.5	5.7	8.9	12.7	3.0	6.9	10.9	15.5	2.8	15.5	100%	16.2	5%
Nesp	0.7	1.4	2.0	2.6	0.5	0.9	1.1	1.4	(1.3)	2.0	71%	0.8	(41)%
Darbepoetin Alfa Injection Syringe [KKF]	2.8	5.6	8.5	11.6	2.3	4.9	7.6	10.4	(1.1)	9.6	109%	9.2	(12)%
G-Lasta	5.8	10.5	15.3	20.5	4.3	9.1	13.7	18.2	(2.4)	17.0	107%	16.2	(11)%
Romiplate	3.0	6.5	9.9	13.9	3.4	7.3	11.5	15.9	2.0	14.6	109%	11.4	(28)%
Orkedia	2.2	4.9	7.5	10.4	2.4	5.4	8.2	11.3	0.9	10.7	106%	11.6	3%
Rituximab BS [KKH]	1.9	3.8	5.7	7.8	1.5	3.2	5.0	6.9	(1.0)	6.0	114%	7.9	16%
Nourias	1.5	3.4	5.1	6.9	1.4	3.1	4.6	6.3	(0.6)	6.5	97%	5.1	(19)%
HARUROPI	1.0	2.2	3.3	4.6	1.0	2.1	3.3	4.5	(0.0)	4.8	95%	4.0	(12)%
Dovobet ^{*2}	1.8	3.9	5.8	7.9	-	-	-	-	(7.9)	-	-	-	-
Technology out-licensing ^{*3}	12.1	24.3	34.9	48.8	13.0	25.5	39.4	58.4	9.7	52.3	112%	74.9	28%
Benralizumab royalty ^{*4}	6.4	14.4	21.6	31.4	7.4	15.7	25.4	38.1	6.7				
Total	105.6	233.0	362.8	495.6	104.7	230.7	349.5	496.8	1.3	478.0		520.0	

<Quarterly>

Unit: Billions of yen

	FY 2024 results				FY 2025 results				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount
Products ^{*1}	93.4	115.3	119.2	118.9	91.8	113.4	104.9	128.3	9.4
Crysvita	37.8	53.0	44.0	61.7	42.4	57.3	46.9	69.7	8.0
Poteligeo	8.6	10.4	10.0	10.8	9.8	11.8	12.1	12.0	1.2
Libmeldy/Lenmeldy	1.1	0.3	0.7	1.1	2.1	2.3	(0.0)	2.0	0.9
Nourianz	1.6	2.0	2.6	2.6	2.0	2.6	2.3	2.6	(0.0)
PHOZEVEL	0.6	1.1	1.2	1.8	1.5	2.1	2.2	2.3	0.6
Duvroq	2.5	3.2	3.3	3.8	3.0	3.8	4.1	4.6	0.8
Nesp	0.7	0.7	0.6	0.7	0.5	0.4	0.3	0.3	(0.4)
Darbepoetin Alfa Injection Syringe [KKF]	2.8	2.8	2.9	3.1	2.3	2.6	2.7	2.8	(0.3)
G-Lasta	5.8	4.7	4.8	5.2	4.3	4.8	4.6	4.5	(0.7)
Romiplate	3.0	3.4	3.5	4.0	3.4	3.9	4.2	4.4	0.4
Orkedia	2.2	2.7	2.5	3.0	2.4	2.9	2.9	3.1	0.1
Rituximab BS [KKH]	1.9	1.9	1.9	2.1	1.5	1.7	1.8	1.8	(0.3)
Nourias	1.5	1.9	1.7	1.9	1.4	1.7	1.6	1.7	(0.2)
HARUROPI	1.0	1.2	1.1	1.3	1.0	1.2	1.1	1.3	(0.0)
Dovobet ^{*2}	1.8	2.1	1.8	2.1	-	-	-	-	(2.1)
Technology out-licensing ^{*3}	12.1	12.2	10.7	13.8	13.0	12.5	13.9	19.1	5.3
Benralizumab royalty ^{*4}	6.4	8.0	7.1	9.9	7.4	8.3	9.7	12.7	2.9
Total	105.6	127.4	129.8	132.8	104.7	125.9	118.8	147.4	14.6

^{*1} For revenue for Japan, the figures shown are those before the deduction of discounts and other items, and for revenue for overseas, the figures shown are those after the deduction of discounts and other items and include the impact of exchange rates.

^{*2} Due to the termination of the distribution and co-promotion agreement with LEO Pharma K.K. for Dovobet, sales by the Company ended on December 31, 2024.

^{*3} Revenue listed as "Technology out-licensing" represents the upfront income, milestone revenue and running royalty income that are obtained based on licensing agreements recognizing the granting to third parties the rights for development, manufacturing and sales of the Group's pipeline compounds or the use of technology, etc.

^{*4} Benralizumab royalty only refers to the royalty on sales of Fasenra by AstraZeneca (including the Company's own estimates).

III. Status of Main Products

2. Revenue by Location

<Accumulative>

Unit: Billions of yen

Product name	FY 2024 results				FY 2025 results							FY 2026 forecasts	
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec	Change amount	Jan - Dec latest forecasts	% of forecasts	Jan - Dec	Rate of change
Crysvita	37.8	90.9	134.9	196.6	42.4	99.8	146.7	216.4	19.8	210.2	103%	235.4	9%
Japan	2.5	5.4	8.2	11.7	2.8	6.1	9.7	13.6	1.9	13.1	104%	14.7	8%
North America	22.8	58.7	87.2	130.0	24.1	64.0	92.0	141.8	11.7				
[Millions of USD]	155	388	575	860	157	430	620	946	86				
EMEA	11.9	25.4	37.1	51.5	14.8	28.0	42.4	57.5	6.0	197.1	103%	220.7	9%
[Millions of GBP]	64	133	193	267	77	145	219	293	26				
Others	0.6	1.3	2.3	3.3	0.8	1.7	2.6	3.5	0.3				
Poteligeo	8.6	* 19.1	* 29.1	39.9	9.8	21.6	33.7	45.7	5.8	45.4	101%	54.6	20%
Japan	0.4	1.0	1.4	1.8	0.3	0.7	1.2	1.6	(0.2)	1.9	86%	1.4	(12)%
North America	6.3	14.1	21.6	29.7	6.9	16.0	25.1	33.9	4.2	34.1	100%	40.9	21%
[Millions of USD]	43	93	143	197	45	107	169	227	30	235	97%	273	20%
EMEA	1.9	3.9	6.0	8.2	2.6	4.9	7.3	10.0	1.8	9.2	109%	12.0	20%
[Millions of GBP]	10	21	31	43	13	25	38	51	8	48	105%	59	15%
Others	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.0	0.3	52%	0.2	63%
Libmeldy/Lenmeldy	1.1	1.4	2.2	3.3	2.1	4.4	4.4	6.4	3.1	6.9	93%	10.0	56%
US	-	-	-	-	1.1	1.6	1.6	2.9	2.9			4.5	57%
EMEA	1.1	1.4	2.2	3.3	1.0	2.8	2.8	3.5	0.2			5.5	56%

* The underlined portion indicates that the amount has been changed from the amount [19.0] and [29.0] presented in "Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2025 Second Quarter".

<Quarterly>

Unit: Billions of yen

Product name	FY 2024 results				FY 2025 results				
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec	Change amount
Crysvita	37.8	53.0	44.0	61.7	42.4	57.3	46.9	69.7	8.0
Japan	2.5	2.9	2.8	3.6	2.8	3.3	3.6	3.9	0.4
North America	22.8	35.9	28.6	42.8	24.1	39.9	28.0	49.8	7.0
[Millions of USD]	155	233	187	285	157	273	191	325	40
EMEA	11.9	13.5	11.7	14.4	14.8	13.2	14.4	15.1	0.7
[Millions of GBP]	64	70	59	74	77	68	74	74	0
Others	0.6	0.7	0.9	1.0	0.8	1.0	0.9	0.9	(0.1)
Poteligeo	8.6	10.4	10.0	10.9	9.8	11.8	12.1	12.0	1.1
Japan	0.4	0.5	0.4	0.5	0.3	0.4	0.5	0.5	0.0
North America	6.3	7.8	7.5	8.1	6.9	9.1	9.1	8.8	0.8
[Millions of USD]	43	51	49	54	45	62	62	58	4
EMEA	1.9	2.0	2.0	2.3	2.6	2.3	2.5	2.7	0.4
[Millions of GBP]	10	10	10	12	13	12	13	13	2
Others	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Libmeldy/Lenmeldy	1.1	0.3	0.7	1.1	2.1	2.3	(0.0)	2.0	0.9
US	-	-	-	-	1.1	0.5	(0.0)	1.3	1.3
EMEA	1.1	0.3	0.7	1.1	1.0	1.8	(0.0)	0.7	(0.4)

* The revenue, generated in various currencies inside each corporate region, is converted and aggregated in USD for North America and in GBP for EMEA.

* Revenue that was classified under "APAC" in 2024, will be included in "Others" starting from 2025 due to the business reorganization in the APAC region.

III. Status of Main Products

3. Collaboration Product

<Accumulative>

Unit: Billions of yen

Product name	FY2025 results			
	Jan - Mar	Jan - Jun	Jan - Sep	Jan - Dec
KOMZIFTI ^{*1}				
Revenue	-	-	-	0.3
[Millions of USD]	-	-	-	2
Profit/Loss	(1.3)	(3.1)	(5.5)	(8.2)
[Millions of USD]	(8)	(20)	(37)	(55)
Our group (50% share)				
Revenue	-	-	-	-
Selling, general and administrative expenses	(0.6)	(1.5)	(2.8)	(4.1)
Core operating profit ^{*2}	(0.6)	(1.5)	(2.8)	(4.1)
Amortization (intangible assets)	-	-	-	(0.7)
Profit before tax	(0.6)	(1.5)	(2.8)	(4.8)

<Quarterly>

Unit: Billions of yen

Product name	FY2025 results			
	Jan - Mar	Apr - Jun	Jul - Sep	Oct - Dec
KOMZIFTI ^{*1}				
Revenue	-	-	-	0.3
[Millions of USD]	-	-	-	2
Profit/Loss	(1.3)	(1.8)	(2.5)	(2.7)
[Millions of USD]	(8)	(12)	(17)	(18)
Our group (50% share)				
Revenue	-	-	-	-
Selling, general and administrative expenses	(0.6)	(0.9)	(1.2)	(1.3)
Core operating profit ^{*2}	(0.6)	(0.9)	(1.2)	(1.3)
Amortization (intangible assets)	-	-	-	(0.7)
Profit before tax	(0.6)	(0.9)	(1.2)	(2.1)

^{*1} For KOMZIFTI, under the strategic collaboration agreement with Kura Oncology, profits in the United States will be shared on a 50:50 basis.

The Group records the net profit or loss after profit sharing as revenue when it is positive and as selling, general and administrative expenses when it is negative; in the current consolidated fiscal year, the net result was negative and therefore has been recorded under selling, general and administrative expenses.

^{*2} This is core operating profit based on the new definition. For details, please refer to "I. Consolidated Financial Results:

2. Trends in consolidated profit (Based on the newly defined Core Operating Profit)

IV. R&D pipeline

small molecule
 antibody
 HSC-GT








Updated since Dec. 31, 2024

Updated since Sep. 30, 2025

As of Dec 31, 2025

Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
			PhI	PhII	PhIII	
KK8123 Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia				[In-House] Clinical study is being conducted in NA and EU as a global product
KK8398 infigratinib Oral	FGFR3 Inhibitor	Achondroplasia				[QED Therapeutics] Clinical study is being conducted in JP
		Hypochondroplasia				Preparation underway for Ph III clinical trial in JP
ziftomenib ※ Oral	Menin Inhibitor	Acute Lymphoblastic Leukemia (ALL) (Monotherapy)				[Kura Oncology] Clinical study is being conducted in NA and EU as a global product KMT2A-rearranged ALL KOMET-001
		Acute Myeloid Leukemia (AML) (Monotherapy)				Clinical study is being conducted in NA and EU as a global product Non-NPM1-mutant AML/Non-KMT2A-rearranged AML KOMET-001
						Adult Relapsed or Refractory AML with a NPM1 Mutation Preparation underway for Ph II clinical trial in JP
		Acute Myeloid Leukemia (AML) (Combination)				Clinical study is being conducted in NA as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-007
						Clinical study is being conducted in NA as a global product FLT3/NPM1 co-mutated AML Combinations with cytarabine + daunorubicin, and quizartinib KOMET-007
						Clinical study is being conducted in NA and EU as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with gilteritinib, FLAG-IDA, LDAC KOMET-008
						Clinical study is being conducted as a global product NPM1-mutant AML/KMT2A-rearranged AML Combinations with venetoclax + azacitidine, and cytarabine + daunorubicin KOMET-017
KK2845	Anti-TIM-3 ADC	Acute Myeloid Leukemia (AML)				[In-House] Antibody-Drug Conjugate Clinical study is being conducted in JP as a global product
OTL-203	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IH (Hurler Syndrome)				[In-House] Rare Pediatric Disease (RPD) and Fast Track designations (FDA) Priority Medicines (PRIME) designation (EMA) Area of clinical study: NA and EU
OTL-201	Hematopoietic Stem Cell (HSC) Gene Therapy	MPS-IIIA (Sanfilippo Syndrome type A)				[In-House] Rare Pediatric Disease (RPD) designation (FDA) Preparation underway for registrational study (equivalent to Ph III study)
KHK4083/AMG 451 rocatinlimab Injection	Anti-OX40 Antibody	Moderate to Severe Atopic Dermatitis				[In-House] POTELLIGENT Human monoclonal antibody production technology Collaboration agreement with Amgen for the development of rocatinlimab in all the countries except for Japan Clinical study is being conducted in JP, NA, EU, UK, Middle East, Asia, Oceania, and other regions as a global product
		Prurigo Nodularis				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
		Moderate to Severe Asthma				Clinical study is being conducted in JP, NA, EU, Asia, and Oceania as a global product
KHK4951 tivozanib Ophthalmic	VEGF Receptor Tyrosine Kinase Inhibitor	Diabetic Macular Edema				[In-House] Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
		Neovascular Age-Related Macular Degeneration				Clinical study is being conducted in JP, NA, Asia, and Oceania as a global product
KK2260 Injection	EGFR-TFR1Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP, and a clinical study is prepared under way for PhI in NA as a global product

IV. R&D pipeline

	Code Name Generic Name	Mechanism of Action	Indication	Stage			[In-House or Licensed] Remarks
				PhI	PhII	PhIII	
	KK2269 Injection	EpCAM-CD40Bispecific Antibody	Advanced or Metastatic Solid Tumors				[In-House] REGULGENT Fully human antibody production technology Clinical study is being conducted in JP and NA as a global product
	KK4277 Injection	Anti-PTPRS Humanized Antibody	Systemic Lupus Erythematosus/Cutaneous Lupus Erythematosus				[SBI Biotech] POTELLIGENT Clinical study is being conducted in JP and Asia
	KK3910 Injection		Essential Hypertension				[In-House] Clinical study is being conducted in JP as a global product
	OTL-200 atidarsagene autotemcel	Hematopoietic Stem Cell (HSC) Gene Therapy	Early-onset Metachromatic Leukodystrophy (MLD)				[In-House] Orphan Regenerative Medicine Product Designation in JP Preparation underway for clinical trial in JP Product Name in US: Lenmeldy Product Name in Europe: Libmeldy

※ For detailed information on ziftomenib's development status, please refer to Kura Oncology's website. <https://kuraoncology.com/>

Note: Our main progress from December 31, 2025 is as follows

• On January 30, 2026, Kyowa Kirin announced that termination of the current KHK4083/AMG 451 (rocatinlimab)
collaboration with Amgen and Kyowa Kirin will regain control of KHK4083/AMG 451 development and commercialization program.

Major Applications and Approvals

Code Name, Generic Name, Product Name	Indication	Application/Under Review	Countries/Regions Received Approval in 2025
ziftomenib(Product name in the US: KOMZIFTI)	Adult Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) with a Nucleophosmin1 (NPM1) Mutation	—	US